Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Highlights

FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI

Patients with peripheral vascular disease or prior acute myocardial infarction (especially within the first two years after the event)...
solaci -
Learn More
Antithrombotic Anticoagulants

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with atrial fibrillation undergoing PCI seemed never-ending until the RE-DUAL...
solaci -
Learn More
Antiplatelet

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients

 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with...
solaci -
Learn More
Acute coronary syndromes

TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES

Courtesy of SBHCI. This new device has, on one hand, an abluminal sirolimus coating, and on the other...
solaci -
Learn More
Antiplatelet

Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?

Fentanyl is a potent opiate commonly administered in the cath lab. Recently, questions on its safety have...
solaci -
Learn More
HIGHLIGHTS

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients;...
solaci -
Learn More
Antithrombotic Anticoagulants

COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease

Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable...
solaci -
Learn More
HIGHLIGHTS

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Dr. Omar Tupayachi - 0
Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these...

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Dr. Omar Tupayachi - 0
Coronary perforations during PCI are one of the most dreaded complications in interventional cardiology, especially in bifurcations. Though rate, this critical situation requires an...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy